TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8173242
Drug: VDT work
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VDT work (more than 6 hours daily)
Study: 3555513
Drug: Bardac-22 (didecyl-dimethyl-ammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardac-22 (didecyl-dimethyl-ammonium chloride) in combination with prednicarbate
Study: 19687490
Drug: TwHF extract,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TwHF extract, 60 mg 3 times daily
Study: 19687490
Drug: sulfasalazine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfasalazine, 1 g twice daily
Study: 8325046
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of oral sulodexide (enteric-coated tablets)
Study: 8325046
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of oral sulodexide (enteric-coated tablets)
Study: 8325046
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of sulodexide (100 mg/day and 200 mg/day)
Study: 8325046
Drug: Sulodexide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide (oral administration)
Study: 30439760
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt (200 mL daily with Lactobacillus acidophilus La‐5, Bifidobacterium animalis subsp. lactis Bb‐12, Lactobacillus casei subsp. casei Lc‐01)
Study: 30439760
Drug: Placebo yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo yogurt (200 mL daily with Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus)
Study: 25729066
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (combined superficial and perforating vein surgery)
Study: 25729066
Drug: Ambulatory compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ambulatory compression therapy
Study: 18220219
Drug: Biolight therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biolight therapy
Study: 23967083
Drug: 15% DEET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% DEET lotion
Study: 21679156
Drug: Cerebrolysin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (10 ml)
Study: 21679156
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Cerebrolysin and Donepezil
Study: 16603032
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) plus medication (fluvoxamine)
Study: 16603032
Drug: Medication (fluvoxamine)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (fluvoxamine)
Study: 22417901
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) - 1 g loading dose infused over 10 minutes followed by 1 g intravenous infusion over 8 hours
Study: 21058191
Drug: High-dose isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose isoflavone supplement (450 mg genistein, 300 mg daidzein) daily for 6 months
Study: 11212979
Drug: Indapamide SR
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide SR 1.5 mg (in ISH subgroup)
Study: 11212979
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg (in ISH subgroup)
Study: 9371301
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin administered using a validated protocol
Study: 2701030
Drug: Doxofylline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline 200 mg sachets, administered at a daily dose of 12 mg/kg for 14 days.
Study: 23929928
Drug: Febuxostat (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (80 mg)
Study: 22178829
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg rosiglitazone treatment group
Study: 16238680
Drug: Atorvastatin or
Normalized name: atorvastatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin or simvastatin therapy
Study: 10210737
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (2 effervescent tablets of 400 mg)
Study: 10210737
Drug: Paracetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (2 effervescent tablets of 500 mg)
Study: 10210737
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 effervescent tablets)
Study: 295279
Drug: Oxazepam 30
Normalized name: oxazepam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 30 mg for one week
Study: 25773354
Drug: FE 999049
Normalized name: Fe
DrugBank: Ferric cation (DB13949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE 999049 (rFSH) administered subcutaneously at doses of 37.5, 75, 150, 225, or 450 IU
Study: 25773354
Drug: FE 999049
Normalized name: Fe
DrugBank: Ferric cation (DB13949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE 999049 (rFSH) administered subcutaneously
Study: 3202132
Drug: Adenosine triphosphate
Normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine triphosphate (ATP) 300 mg daily for 4 weeks
Study: 3202132
Drug: Betahistine 36
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 36 mg daily for 4 weeks
Study: 25896182
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (FO) 10 g daily for 12 weeks
Study: 25896182
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (CO) 10 g daily for 12 weeks
Study: 16025252
Drug: Metformin or
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin or Sulphonylurea (non-rosiglitazone group)
Study: 7746913
Drug: Placebo (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (chemotherapy alone)
Study: 2139286
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine alone (10 micrograms)
Study: 2139286
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA hepatitis B vaccine + hepatitis B immune globulin (HBIg) (10 micrograms + 0.5 ml HBIg)
Study: 6993109
Drug: Sulphadiazine 225
Normalized name: Sulphadiazine
DrugBank: Sulfadiazine (DB00359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphadiazine 225 mg and Trimethoprim 75 mg (SD/TMP)
Study: 6993109
Drug: Sulphamethoxazole 400
Normalized name: Sulphamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphamethoxazole 400 mg and Trimethoprim 80 mg (SM/TMP)
Study: 23648219
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium nitrite administration prior to percutaneous coronary intervention (PCI)
Study: 23648219
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium nitrite administration
Study: 21663644
Drug: DNA quality
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA quality assessment via gel electrophoresis QC and TaqMan genotyping
Study: 18604045
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group (ventilated with tidal volume of 10 ml/kg and respiratory rate of 15/minute)
Study: 18604045
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ventilated with tidal volume of 10 ml/kg and respiratory rate of 12/minute)
Study: 14999362
Drug: Ultrahaler (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrahaler (3 mg)
Study: 14999362
Drug: Nebulizer (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulizer (3 mg)
Study: 10611198
Drug: Continuous autotransfusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous autotransfusion system of ascites (CATSA) performed for 5 hours at a rate of 100-200 ml/h once a day
Study: 10611198
Drug: Intravenous albumin
Normalized name: albumin human, USP Injection [Albuminar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous albumin supplement (37.5 g/day)
Study: 9189783
Drug: Preexercise carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preexercise carbohydrate (CHO) feedings (22.5, 45, or 75 g maltodextrin and dextrose in 473 ml of water)
Study: 1555806
Drug: Indomethacin gel
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin gel preparation 1
Study: 1555806
Drug: Indomethacin gel
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin gel preparation 2
Study: 1555806
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo or alternative treatment not specified)
Study: 26780289
Drug: Relapse to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse to injecting drug use (IDU) after treatment
Study: 26780289
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of IDU prior to treatment
Study: 24275909
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), 20 sessions over 5 months
Study: 24275909
Drug: Psychoanalytic psychotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic psychotherapy, 2 years of weekly sessions
Study: 22697453
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP), n=26
Study: 16134133
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug (low and high dose)
Study: 11821469
Drug: Preirradiation chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preirradiation chemotherapy (2 cycles of ifosfamide, etoposide, methotrexate, cisplatin, and cytarabine), n = 40
Study: 11821469
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after irradiation (8 cycles with cisplatin, vincristine, and lomustine), n = 23
Study: 11821469
Drug: Irradiation (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation (total dose of 35.2 Gy followed by a boost of 20.0 Gy to the primary tumor site), n = 54
Study: 11821469
Drug: Irradiation (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation (total dose of 54.0 Gy to the tumor region only), n = 7
Study: 10402369
Drug: L-arginine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine treatment
Study: 7747293
Drug: 4 ampoules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ampoules (40 mL) of Brazilian Brothrops polyspecific antivenom
Study: 7747293
Drug: 2 ampoules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ampoules (20 mL) of Brazilian Brothrops polyspecific antivenom
Study: 2206784
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg verapamil i.v. (8 patients)
Study: 2206784
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg isosorbide dinitrate sublingually (12 patients)
Study: 2206784
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (7 patients)
Study: 24525963
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (vancomycin/cefepime or piperacillin/tazobactam)
Study: 24525963
Drug: No preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preventive antibiotics (Control)
Study: 19789884
Drug: iobitridol (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: iobitridol (350 mgI/ml)
Study: 19789884
Drug: iomeprol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol (400 mgI/ml)
Study: 10811045
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy Programme (MTP)
Study: 10811045
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment programmes
Study: 30698049
Drug: Preventive swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive swallowing exercise program (3 weekly supervised sessions of 30 min each and home-based exercises 3 times daily)
Study: 26667088
Drug: Aspirin-calcitriol-calcium treatment
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin-calcitriol-calcium treatment
Study: 22934397
Drug: Thermal acupuncture
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal acupuncture needle muscular stimulation therapy, conducted once a week for 4 weeks.
Study: 22934397
Drug: Celebrex (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celebrex (200 mg, once daily for 4 weeks)
Study: 20058569
Drug: 20 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml/kg of Ringer's lactate
Study: 20058569
Drug: 10 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg of Ringer's lactate
Study: 12481630
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy with dexamethasone 0.6 mg/kg/day in 3 divided doses for 4 days
Study: 12481630
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy alone (benzyl penicillin and chloramphenicol for 14 days)
Study: 10941
Drug: Flurazepam hydrochloride
Normalized name: Flurazepam Hydrochloride
DrugBank: Flurazepam (DB00690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurazepam hydrochloride (30 mg)
Study: 10941
Drug: Pentobarbitone sodium
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentobarbitone sodium (200 mg)
Study: 28213957
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg kg‐1 b.i.d.
Study: 28213957
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg kg‐1 t.i.d.
Study: 21682833
Drug: Alogliptin 12.5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg added to pioglitazone
Study: 21682833
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg added to pioglitazone
Study: 21682833
Drug: Alogliptin (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (12.5 or 25 mg) during the 40-week extension
Study: 11836292
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH therapy at 27 IU (9 mg)/m(2) x wk
Study: 11836292
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH therapy at 18 IU (6 mg)/m(2) x wk
Study: 10343539
Drug: Antikeratin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antikeratin antibodies (AKA)
Study: 10343539
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to human epidermis filaggrin (AFA)
Study: 10343539
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of APF and AKA
Study: 10343539
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AFA and AKA
Study: 8960842
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control (systolic < 150/diastolic < 85 mmHg) with beta blocker (atenolol) or ACE inhibitor (captopril)
Study: 6819904
Drug: Oral TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TRH (20 mg twice daily)
Study: 6819904
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide (10 mg t.d.s.)
Study: 29029687
Drug: Net‐COPD telemedicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Net‐COPD telemedicine intervention with weekly submission of readings and regular video consultations
Study: 17318620
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of the same vaccine
Study: 9787142
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (0.3 mg/kg every 12 hours x 4 doses)
Study: 7636912
Drug: High Albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Albumin (supplemental albumin to maintain levels 2.5 to 3.5 g/dL)
Study: 7636912
Drug: Low Albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Albumin (albumin only if levels dropped < 1.5 g/dL)
Study: 237493
Drug: Alclofenac 3
Normalized name: Acéclofénac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alclofenac 3 g
Study: 237493
Drug: Phenylbutazone 300
Normalized name: phenylbutazone 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 300 mg
Study: 30859363
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (30 mg/kg/day)
Study: 30859363
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (60 mg/kg/day)
Study: 31227681
Drug: Low-dose wide-detector
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose wide-detector scan (experimental group)
Study: 31227681
Drug: Low-dose helical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose helical scan (low-dose helical group)
Study: 9029752
Drug: 1-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g oral dose of vigabatrin
Study: 9029752
Drug: 2-g and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g and 4-g oral doses of vigabatrin
Study: 9029752
Drug: 0.75-g dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75-g dose of vigabatrin in renal failure patients
Study: 8498730
Drug: terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 60 mg/pseudoephedrine hydrochloride 120 mg (T/Ps)
Study: 8498730
Drug: clemastine fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clemastine fumarate 1.34 mg/phenylpropanolamine 75 mg (C/Ph)
Study: 3278574
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sublingual nifedipine (group 1)
Study: 31957334
Drug: TDM-guided dosing
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDM-guided dosing
Study: 31957334
Drug: Current practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current practice (160 mg/m2)
Study: 31455386
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 0 μg.ml ‐1
Study: 31455386
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 0.5 μg.ml ‐1
Study: 31455386
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 1.0 μg.ml ‐1
Study: 16108508
Drug: Topical anti-histamine/decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anti-histamine/decongestant eye drops
Study: 12126869
Drug: Amisulpride (400‐800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (400‐800 mg/day, n = 339)
Study: 12126869
Drug: Haloperidol (15‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (15‐20 mg/day, n = 160)
Study: 12126869
Drug: Risperidone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (8 mg/day, n = 113)
Study: 7806817
Drug: Continuous splinting
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous splinting (early treatment)
Study: 7806817
Drug: Continuous splinting
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous splinting (delayed treatment)
Study: 2699608
Drug: Tranylcypromine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranylcypromine (5 mg once a day)
Study: 30579342
Drug: Tetracaine mucilage
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracaine mucilage in combination with image illustration on CRBD
Study: 25415158
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (450 mg per day)
Study: 19036079
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (ara‐C) therapy with IDA‐FLAG (ara‐C = 7590 mg/m2)
Study: 19036079
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (ara‐C) therapy with IDA‐DCTER (ara‐C = 800 mg/m2)
Study: 19036079
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (ara‐C) therapy with IDA‐FLAG
Study: 19036079
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (ara‐C) therapy
Study: 17935765
Drug: salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol/fluticasone propionate combination (SFC)